Is AstraZeneca’s Pipeline Fuel Enough to Spark a Post-Earnings Breakout on Oct. 30?
AstraZeneca heads into its October 30 earnings call with oncology surging and its cardiology franchise under pressure, leaving investors to wonder whether new drug launches can absorb the losses fast enough to justify a breakout.
AstraZeneca (NYSE:AZN | AZN Price Prediction) reports third-quarter results on Friday, October 30. Farxiga generics are cutting into sales, and a major cardiology trial has failed. This report shows whether oncology and new launches can still carry growth.
Oncology Strength Meets a Bruised Cardio Franchise
Last quarter, revenue reached $15.38B, up 6.4% year over year but slightly short of the $15.42B consensus. Core EPS of $2.63 beat expectations again, and core operating margin expanded 2 points to 34%.
The product mix explains the quarter. Oncology grew 15% to $6.71B, led by Imfinzi (+27%) and Enhertu (+47%). Over the same stretch, Farxiga fell 16% after U.S. generics arrived. Excluding Farxiga and Brilinta, first-half revenue rose 11%.
Wainua then failed the CARDIO-TTRansform Phase III trial. Since that setback, U.S. regulators have approved Baxfendy for hypertension, Datroway in first-line triple-negative breast cancer, and new Enhertu and Imfinzi indications. Shares rose 5.42% over the past month to $172.19 but are still down 3.75% year to date.
Wall Street Expects Mid-Single-Digit Top-Line Growth
| Metric | Consensus | YoY Change |
|---|---|---|
| Q3 2026 EPS (per ADS) | $1.1457 | -3.7% |
| Q3 2026 Revenue | $16.0B | 5.3% |
| FY 2026 EPS | $10.05 | 9.7% |
| FY 2026 Revenue | $63.29B | 7.8% |
The Q3 EPS comparison converts last year’s core EPS of $2.38 per share to an ADS basis.
Oncology Depth and Farxiga Erosion Will Set the Tone
I’ll watch oncology first. Tagrisso grew only 7% last quarter, so Imfinzi, Enhertu and Calquence now do more of the work. Calquence exceeded $1 billion in quarterly revenue for the first time. Management puts peak sales for the stomach cancer drug sone-ve at $3 billion to $5 billion, and any commercial framing after ESMO matters.
Next is Farxiga. The second quarter was the first full quarter of U.S. generic competition, and Farxiga revenue came in at $1.80B. Whether respiratory products keep filling the gap is worth watching, after Breztri grew 22% and Fasenra 14%. China revenue fell 7% under volume-based procurement, which makes it another pressure point.
Margins come third. Management noted a lower second-half gross margin from seasonal products like FluMist and Beyfortus, plus higher finance costs. Net debt rose to $26.9B, and capex is set to rise by about a third this year.
Finally, the pipeline calendar. Management lists 25 key Phase III readouts over 18 months. SERENA-4, TROPION-Lung15 and SAFFRON are all due later in 2026.
A Chance to Prove the $80 Billion Path Still Holds
CEO Pascal Soriot said the “$80bn Total Revenue ambition” already assumes both successes and setbacks. History shows that beating estimates alone won’t move the stock for long. Across six beats, shares averaged a 1.7% day-of gain but just 0.05% over a week. A real breakout needs proof that new launches are outpacing patent losses.
Contact [email protected] for any questions or corrections.
After two decades of patrolling the dark corners of suburbia as a police officer, Rich Duprey hung up his badge and gun to begin writing full time about stocks and investing. For the past 20 years, he’s been cruising the markets looking for companies to lock up as long-term holdings in a portfolio while writing extensively on the broad sectors of consumer goods, technology, and industrials. Because his experience isn’t from the typical financial analyst track, Rich is able to break down complex topics into understandable and useful action points for the average investor. His writings have appeared on The Motley Fool, InvestorPlace, Yahoo! Finance, Money Morning, and, of course, 24/7 Wall St. He has been featured in both U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, and USA Today.
